Document is current
Any future updates will be listed below
-
Authors
Caballero-Ávila, Marta https://orcid.org/0000-0001-9850-8504
Pascual-Goñi, Elba
Lleixà, Cinta
Martín-Aguilar, Lorena https://orcid.org/0000-0002-1553-2224
Collet-Vidiella, Roger https://orcid.org/0000-0003-1668-1018
Querol, Luis https://orcid.org/0000-0002-4289-8264
- License Information
-
More Information
Article History
Accepted: 14 August 2025
First Online: 5 September 2025
Competing interests
: L.Q. has received research grants from ArgenX, speaker or expert testimony honoraria from Alnylam, Annexon, ArgenX, Avilar Therapeutics, Biocryst, CSL Behring, Dianthus, LFB, Lycia Therapeutics, Merck, Montis, Novartis, Nuvig Therapeutics, Sanofi-Genzyme and Takeda, serves on Clinical Trial Steering Committees for ArgenX, Sanofi-Genzyme and Takeda and is Principal Investigator of trials for UCB (CIDP01 trial) and Sanofi-Genzyme (Mobilize and Vitalize trials). All other authors declare no competing interests.
